Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and seven have issued a b...
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and seven have issued a b...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gainers
Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q3 earningsread more...
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.